Affordable Access

deepdyve-link
Publisher Website

Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.

Authors
  • Kondo, Toshinori
  • Okuno, Nanako
  • Naruse, Hiromu
  • Kishimoto, Mitsuyo
  • Tasaka, Taizo
  • Tsujioka, Takayuki
  • Matsuoka, Akihito
  • Sugihara, Takashi
  • Tohyama, Yumi
  • Tohyama, Kaoru
Type
Published Article
Journal
Leukemia & Lymphoma
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 01, 2008
Volume
49
Issue
9
Pages
1784–1791
Identifiers
DOI: 10.1080/10428190802258972
PMID: 18661406
Source
Medline
License
Unknown

Abstract

The objective of this study was to validate the recently revised 2008 WHO diagnostic criteria of myeloproliferative neoplasms (MPN) together with the analysis of correlation of JAK2 (Janus kinase 2)-V617F mutant allele burden with clinical/laboratory findings on each patient. We made a diagnosis of 75 suspected MPN patients based on both diagnostic criteria of the 2001 WHO classification and the revised 2008 WHO classification, and found that both criteria show a quite similar diagnostic power except for two patients (idiopathic erythrocytosis (IE) and thrombocytosis) who were diagnosed as essential thrombocythemia by the 2008 WHO criteria. From JAK2-V617F analysis, hemoglobin and hematocrit values were significantly higher and platelet count was lower in JAK2-V617F high allele burden group than JAK2-V617F middle allele burden group. Mutant allele burden of polycythemia vera (PV) group was higher than that of essential thrombocythemia group. Therefore, the amount of mutant allele seemed to define the disease phenotypes. We further found a PV case presenting a rare type of JAK2-exon12 mutation. In contrast, IE presented a good prognosis unlike MPN. Hereafter, the 2008 WHO criteria with JAK2 gene analysis are useful for precise diagnosis of MPN and the patients with erythrocytosis.

Report this publication

Statistics

Seen <100 times